IDN-6556

Phase 2Small molecule

CConatus Pharmaceuticals Inc.

IDN-6556 is one of 149 small molecule programs targeting Liver Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

HepatitisActive, not recruiting

Portal HypertensionActive, not recruiting

Chronic HepatitisActive, not recruiting

CirrhosisActive, not recruiting

Liver TransplantPhase 2

Active, not recruiting

HepatitisPhase 2

Active, not recruiting

Portal HypertensionPhase 2

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

CirrhosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

IDN-6556

CConatus Pharmaceuticals Inc.

Phase 2

1 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Interferon Alfa

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Transplant2 trials

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT00080236·99 enrolled

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT02138253·64 enrolled

Hepatic Impairment1 trial

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

Completed·CConatus Pharmaceuticals Inc.·Phase 1·NCT02121860·37 enrolled

NAFLD1 trial

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT02077374·38 enrolled

Cirrhosis1 trial

A Study of IDN-6556 in Subjects With Liver Cirrhosis

Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT02230670·87 enrolled

Hepatitis1 trial

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

Terminated·CConatus Pharmaceuticals Inc.·Phase 2·NCT01912404·5 enrolled

5 more indications

ACL1 trial

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Terminated·CConatus Pharmaceuticals Inc.·Phase 2·NCT01937130·23 enrolled

Islet Transplantation1 trial

Caspase Inhibition in Islet Transplantation

Completed·UUniversity of Alberta·Phase 1/2·NCT01653899·12 enrolled

Portal Hypertension1 trial

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT02230683·23 enrolled

Renal Impairment1 trial

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

Completed·CConatus Pharmaceuticals Inc.·Phase 1·NCT02039817·16 enrolled

Chronic Hepatitis1 trial

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT00088140·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for IDN-6556. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IDN-6556 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IDN-6556. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Conatus Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CConatus Pharmaceuticals Inc.

IDN-6556

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Transplant2 trials

Hepatic Impairment1 trial

NAFLD1 trial

Cirrhosis1 trial

Hepatitis1 trial

ACL1 trial

Islet Transplantation1 trial

Portal Hypertension1 trial

Renal Impairment1 trial

Chronic Hepatitis1 trial

References

Drug Info

Quick Facts

Related News